New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.

Abstract:

:Both seasonal and pandemic influenza cause considerable morbidity and mortality globally. In addition, the ongoing threat of new, unpredictable influenza pandemics from emerging variant strains cannot be underestimated. Recently bioCSL (previously known as CSL Biotherapies) sponsored a symposium 'New Wisdom to Defy an Old Enemy' at the 4th Influenza Vaccines for the World Congress in Valencia, Spain. This symposium brought together a renowned faculty of experts to discuss lessons from past experience, novel influenza vaccine developments, and new methods to increase vaccine acceptance and coverage. Specific topics reviewed and discussed included new vaccine development efforts focused on improving efficacy via alternative administration routes, dose modifications, improved adjuvants, and the use of master donor viruses. Improved safety was also discussed, particularly the new finding of an excess of febrile reactions isolated to children who received the 2010 Southern Hemisphere (SH) trivalent inactivated influenza vaccine (TIV). Significant work has been done to both identify the cause and minimize the risk of febrile reactions in children. Other novel prophylactic and therapeutic advances were discussed including immunotherapy. Standard IVIg and hIVIg have been used in ferret studies and human case reports with promising results. New adjuvants, such as ISCOMATRIX™ adjuvant, were noted to provide single-dose, prolonged protection with seasonal vaccine after lethal H5N1 virus challenge in a ferret model of human influenza disease. The data suggest that adjuvanted seasonal influenza vaccines may provide broader protection than unadjuvanted vaccines. The use of an antigen-formulated vaccine to induce broad protection between pandemics that could bridge the gap between pandemic declaration and the production of a homologous vaccine was also discussed. Finally, despite the availability of effective vaccines, most current efforts to increase influenza vaccine coverage rates to higher levels (i.e., above 70-80%) have been ineffective in highly developed countries where the vaccine is used, hindered by the public's skepticism towards vaccines in general. New educational and social media methods to increase vaccine acceptance and coverage were discussed. While the first priority should be the development of improved influenza vaccines, a particular focus on the aging global population is critical. It is also important to draw lessons from other academic disciplines that can help to inform vaccine education programs, policy, and communication. By tailoring communications and patient education using an understanding of cognitive bias and the model of preferred cognitive styles, the likelihood of effecting desirable health decisions can be maximized, leading to improved vaccine coverage and control of influenza and other vaccine-preventable diseases.

journal_name

Vaccine

journal_title

Vaccine

authors

Poland GA,Fleming DM,Treanor JJ,Maraskovsky E,Luke TC,Ball EM,Poland CM

doi

10.1016/j.vaccine.2013.02.033

subject

Has Abstract

pub_date

2013-04-17 00:00:00

pages

A1-20

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(13)00196-5

journal_volume

31 Suppl 1

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Homologous prime-boost strategy in neonate mice using Neisseria lactamica.

    abstract::The aim of the present study was to investigate the immune response to native outer membrane vesicles (NOMVs) of Neisseria lactamica with and without Bordetella pertussis (BP) as adjuvant in intranasal (i.n./i.m) immunization. N. lactamica NOMVs delivered intranasally (i.n) to BALB/c mice in a final volume of 5microl ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.01.114

    authors: Ito AY,Néri S,Machado MS,Tunes CF,De Gaspari EN

    更新日期:2009-05-26 00:00:00

  • Human schistosomiasis: potential consequences of vaccination.

    abstract::The potential outcomes of a Phase II schistosomiasis vaccine trial are explored using mathematical models which assume some natural immunity and a vaccine providing partial protection for a limited time. Analyses suggest that vaccination may have only a limited impact on life-long cumulative worm burdens and may lead ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(95)00083-d

    authors: Woolhouse ME

    更新日期:1995-08-01 00:00:00

  • Comparison of DNA application methods to reduce BRSV shedding in cattle.

    abstract::We compared the protection afforded by three different DNA application methods against bovine respiratory syncytial virus (BRSV) infection in cattle. A synthetic gene that codes for the G protein of BRSV was inserted into a eukaryotic vector and was used in the vaccine. Intradermal (i.d.) application with a needleless...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(97)00198-9

    authors: Schrijver RS,Langedijk JP,Keil GM,Middel WG,Maris-Veldhuis M,Van Oirschot JT,Rijsewijk FA

    更新日期:1998-01-01 00:00:00

  • Vaccination coverage against 2009 seasonal influenza in chronically ill children and adults: analysis of population registries in primary care in Madrid (Spain).

    abstract::Using electronic clinical records in primary care (ECRPC) of the entire population living in the Autonomous Community of Madrid, Spain (5,102,568 persons) as a data source, this study aimed to ascertain seasonal anti-influenza vaccination coverage in the chronically ill at-risk children (aged 6 months to 14 years) and...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.07.013

    authors: Rodríguez-Rieiro C,Domínguez-Berjón MF,Esteban-Vasallo MD,Sánchez-Perruca L,Astray-Mochales J,Fornies DI,Ordoñez DB,Jiménez-García R

    更新日期:2010-08-31 00:00:00

  • Risk stacking of pneumococcal vaccination indications increases mortality in unvaccinated adults with Streptococcus pneumoniae infections.

    abstract:BACKGROUND:Several chronic disease states have been identified as pneumococcal vaccination indications due to their ability to increase pneumococcal disease development and subsequent mortality. However, the risk of mortality according to the number of these disease states present is unknown. We sought to determine the...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.02.026

    authors: Morton JB,Morrill HJ,LaPlante KL,Caffrey AR

    更新日期:2017-03-23 00:00:00

  • Antibody levels against tetanus and diphtheria after polychemotherapy for childhood sarcoma: a report from the Late Effects Surveillance System.

    abstract:BACKGROUND:It is known that antineoplastic treatment may induce secondary immunodeficiency, but studies after childhood sarcoma are rare. Since 1998, the Late Effects Surveillance System (LESS) of the German Society for Paediatric Oncology and Haematology (GPOH) prospectively registers late effects in soft tissue-, ost...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.vaccine.2010.12.084

    authors: Paulides M,Stöhr W,Laws HJ,Graf N,Lakomek M,Berthold F,Schmitt K,Niggli F,Jürgens H,Bielack S,Koscielniak E,Klingebiel T,Langer T

    更新日期:2011-02-11 00:00:00

  • Scale-up for bulk production of vaccine against meningococcal disease.

    abstract::At the Netherlands Vaccine Institute (NVI) a vaccine against Neisseria meningitidis serogroup B organisms based on different porA subtypes contained in outer membrane vesicles (OMVs) is in advanced stage of development and will be evaluated in clinical trial studies in the near future. In order to meet the expected de...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.06.008

    authors: Baart GJ,de Jong G,Philippi M,van't Riet K,van der Pol LA,Beuvery EC,Tramper J,Martens DE

    更新日期:2007-08-21 00:00:00

  • Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine.

    abstract::Previously, we showed that intracutaneous vaccination of rabbits with DNA vectors encoding ubiquitin-fused versions of the cottontail rabbit papillomavirus (CRPV) early proteins E1, E2, E6 and E7 protected against subsequent challenge with CRPV. Here, we tested the immunotherapeutic activity of a vaccine composed of t...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.06.012

    authors: Brandsma JL,Shlyankevich M,Zelterman D,Su Y

    更新日期:2007-08-14 00:00:00

  • Immunogenicity and protective efficacy of recombinant Haemophilus parasuis SH0165 putative outer membrane proteins.

    abstract::Haemophilus parasuis (H. parasuis), the causative agent of swine polyserositis, polyarthritis, and meningitis, is one of the most important bacterial diseases of pigs worldwide. Little vaccines currently exist that have a significant effect on infections with all pathogenic serovars of H. parasuis. H. parasuis putativ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.11.003

    authors: Fu S,Zhang M,Xu J,Ou J,Wang Y,Liu H,Liu J,Chen H,Bei W

    更新日期:2013-01-02 00:00:00

  • Impact of a 2-dose voluntary vaccination strategy on varicella epidemiology in Beijing, 2011-2017.

    abstract:BACKGROUND:One-dose voluntary varicella vaccination for children was introduced in Beijing since 1998. In Oct 2012, a second dose varicella vaccine (VarV) was recommended to further decrease varicella disease and the outbreaks. We describe the impact of the 2-dose voluntary vaccination strategy on varicella epidemiolog...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.01.087

    authors: Suo L,Lu L,Zhao D,Pang X

    更新日期:2020-04-29 00:00:00

  • A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers.

    abstract::A phase I clinical trial was performed to examine the safety and immunogenicity of a multi-epitope polypeptide comprising the central 15 amino acids of the V3 loop from six HIV-1 isolates. This protein called TAB9 was emulsified in Montanide ISA720 (Seppic, Paris) and administered intramuscularly at doses of 0, 0.2 an...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0264-410x(01)00111-6

    authors: Toledo H,Baly A,Castro O,Resik S,Laferté J,Rolo F,Navea L,Lobaina L,Cruz O,Míguez J,Serrano T,Sierra B,Pérez L,Ricardo ME,Dubed M,Lubián AL,Blanco M,Millán JC,Ortega A,Iglesias E,Pentón E,Martín Z,Pérez J,Dí

    更新日期:2001-07-20 00:00:00

  • Development of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickens.

    abstract::The objective of the present study was to investigate the feasibility of a subunit vaccine and a live bacteria vaccine to protect chickens against infectious bursal disease virus (IBDV) infection. The gene for VP2 of a new wild-type very virulent IBDV (vvIBDV) strain was cloned into an Escherichia coli expression syst...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.05.015

    authors: Rong J,Cheng T,Liu X,Jiang T,Gu H,Zou G

    更新日期:2005-09-23 00:00:00

  • RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial.

    abstract:BACKGROUND:We report the first-in-concept human trial of the safety, tolerability and immunogenicity when a novel TLR 7/8/RIG I agonist RNA-based adjuvant, CV8102, was administered alone or mixed with fractional doses of a licensed rabies vaccine (Rabipur®) as model antigen. METHODS:The primary objective was to assess...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.02.024

    authors: Doener F,Hong HS,Meyer I,Tadjalli-Mehr K,Daehling A,Heidenreich R,Koch SD,Fotin-Mleczek M,Gnad-Vogt U

    更新日期:2019-03-22 00:00:00

  • Mapping financial flows for immunisation in Uganda 2009/10 and 2010/11: New insights for methodologies and policy.

    abstract:BACKGROUND:The Global Vaccine Action Plan highlights the need for immunisation programmes to have sustainable access to predictable funding. A good understanding of current and future funding needs, commitments, and gaps is required to enhance planning, improve resource allocation and mobilisation, and to avoid funding...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.12.053

    authors: Guthrie T,Zikusooka C,Kwesiga B,Abewe C,Lagony S,Schutte C,Marinda E,Humphreys K,Motlogelwa K,Nombewu ZC,Brenzel L,Kinghorn A

    更新日期:2015-05-07 00:00:00

  • Enhancing immune responses to inactivated porcine parvovirus oil emulsion vaccine by co-inoculating porcine transfer factor in mice.

    abstract::Inactivated porcine parvovirus (PPV) vaccines are available commercially and widely used in the breeding herds. However, inactivated PPV vaccines have deficiencies in induction of specific cellular immune response. Transfer factor (TF) is a material that obtained from the leukocytes, and is a novel immune-stimulatory ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.05.077

    authors: Wang RN,Wang YB,Geng JW,Guo DH,Liu F,Chen HY,Zhang HY,Cui BA,Wei ZY

    更新日期:2012-07-27 00:00:00

  • Improving the stability of recombinant anthrax protective antigen vaccine.

    abstract::Development of recombinant protective antigen (rPA)-based anthrax vaccines has been hindered by a lack of stability of the vaccines associated with spontaneous deamidation of asparagine (Asn) residues of the rPA antigen during storage. In this study, we explored the role that two deamidation-prone Asn residues located...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.09.012

    authors: Verma A,Burns DL

    更新日期:2018-10-15 00:00:00

  • Safety, immunogenicity and shedding of LAIV4 in HIV-infected and uninfected children.

    abstract:OBJECTIVES:HIV-infected children have poor responses to inactivated influenza vaccines. Live vaccines (LAIVs) are highly efficacious in children, but they are not used in HIV-infected children du e to limited information. We investigated the safety, immunogenicity and viral shedding of LAIV4 in HIV-infected compared wi...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.07.082

    authors: Curtis D,Ning MF,Armon C,Li S,Weinberg A

    更新日期:2015-09-11 00:00:00

  • Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant.

    abstract::Intranasal (i.n.) vaccination with two suboptimal doses of 8 microg of deglycosylated chain A ricin (DGCA) stimulated low anti-ricin ELISA IgG and neutralizing antibody responses and the vaccine was only marginally protective against a lethal ricin toxin aerosol challenge. However, in the presence of 4, 2, or 1 microg...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.12.034

    authors: Kende M,Del Giudice G,Rivera N,Hewetson J

    更新日期:2006-03-15 00:00:00

  • Oral immunization with a Streptococcal pneumoniae polysaccharide conjugate vaccine in enterocoated microparticles induces serum antibodies against type specific polysaccharides.

    abstract::The authors examined the antibody responses of mice orally immunized with pneumococcal polysaccharide (type 23F) or a pneumococcal polysaccharide conjugated to the outer membrane protein complex of Neisseria meningitides (23F-OMPC). These antigens were administered either in solution or entrapped within microcapsules....

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(98)00118-2

    authors: Flanagan MP,Michael JG

    更新日期:1999-01-01 00:00:00

  • Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.

    abstract:BACKGROUND:Despite its high worldwide morbidity and mortality, there is yet no licensed vaccine for shigellosis. We reported the safety and immunogenicity of Shigella O-specific polysaccharide-protein conjugates in adults and young children and efficacy of Shigella sonnei conjugate in young adults. METHODS:A double-bl...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2009.12.050

    authors: Passwell JH,Ashkenazi S,Banet-Levi Y,Ramon-Saraf R,Farzam N,Lerner-Geva L,Even-Nir H,Yerushalmi B,Chu C,Shiloach J,Robbins JB,Schneerson R,Israeli Shigella Study Group.

    更新日期:2010-03-02 00:00:00

  • Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.

    abstract::Immunological memory induced by nasal immunization with adjuvant-combined influenza vaccine was analyzed in different ages and strains of mice. The memory activities were assessed by secondary nasal-wash IgA and serum IgG antibody (Ab) responses and protection against challenge infection with a lethal dose of influenz...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.06.060

    authors: Asanuma H,Fujihashi K,Miyakoshi T,Yoshikawa T,Fujita-Yamaguchi Y,Kojima N,Nakata M,Suzuki Y,Tamura S,Kurata T,Sata T

    更新日期:2007-09-28 00:00:00

  • Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women.

    abstract::Vaccination during pregnancy is increasingly being used as an effective approach for protecting both young infants and their mothers from serious infections. Drawing conclusions from published studies in this area can be difficult because of the inability to compare vaccine trial results across different studies and s...

    journal_title:Vaccine

    pub_type: 指南,杂志文章

    doi:10.1016/j.vaccine.2016.07.032

    authors: Jones CE,Munoz FM,Spiegel HM,Heininger U,Zuber PL,Edwards KM,Lambach P,Neels P,Kohl KS,Gidudu J,Hirschfeld S,Oleske JM,Khuri-Bulos N,Bauwens J,Eckert LO,Kochhar S,Bonhoeffer J,Heath PT,Brighton Collaboration Immunizat

    更新日期:2016-12-01 00:00:00

  • Multilevel correlates for human papillomavirus vaccination of adolescent girls attending safety net clinics.

    abstract:BACKGROUND:Adolescent HPV vaccination in minority and low income populations with high cervical cancer incidence and mortality could reduce disparities. Safety-net primary care clinics are a key delivery site for improving vaccination rates in these populations. PURPOSE:To examine prevalence of HPV initiation (≥ 1 dos...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.11.031

    authors: Tiro JA,Pruitt SL,Bruce CM,Persaud D,Lau M,Vernon SW,Morrow J,Skinner CS

    更新日期:2012-03-16 00:00:00

  • Immunogenicity of bacteriophage lambda particles displaying porcine Circovirus 2 (PCV2) capsid protein epitopes.

    abstract::Phage lambda particles displaying four immunodominant regions of porcine Circovirus 2 (PCV2) capsid protein (LDP-D-CAP) was shown to be immunogenic in pigs. The immunodominant regions were fused to the carboxyl-terminal of lambda head protein D. Expression of D-CAP on lambda display particles was demonstrated by ELISA...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.08.019

    authors: Gamage LN,Ellis J,Hayes S

    更新日期:2009-11-05 00:00:00

  • Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays.

    abstract::Dengue fever and dengue hemorrhagic fever are endemic throughout tropical and subtropical countries. Four serotypes of dengue viruses (DENV-1 to DENV-4), each with several genotypes including various subclades, are co-distributed in most endemic areas. Infection-neutralizing and -enhancing antibodies are believed to p...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.06.017

    authors: Yamanaka A,Suzuki R,Konishi E

    更新日期:2014-07-23 00:00:00

  • Knowledge, attitudes and beliefs related to seasonal influenza vaccine among pregnant women in Thailand.

    abstract:BACKGROUND:In 2009, Thailand recommended pregnant women be prioritized for influenza vaccination. Vaccine uptake among Thai pregnant women is lower than other high-risk groups. METHODS:During December 2012-April 2013, we conducted a cross-sectional survey of a convenience sample of Thai pregnant women aged ≥ 15 years ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.01.056

    authors: Ditsungnoen D,Greenbaum A,Praphasiri P,Dawood FS,Thompson MG,Yoocharoen P,Lindblade KA,Olsen SJ,Muangchana C

    更新日期:2016-04-19 00:00:00

  • A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2.

    abstract::Enterohemorrhagic Escherichia coli (EHEC) produces Stx1 and Stx2 causing severe diseases. Their B-subunits (StxBs) exhibit low immunogenicity and the anti-StxB antibodies neutralizing both Stxs has not been prepared yet. By intranasal vaccination with His-tagged-StxB (Stx1B-His or Stx2B-His) plus a mutant heat-labile ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.02.034

    authors: Tsuji T,Shimizu T,Sasaki K,Tsukamoto K,Arimitsu H,Ochi S,Shimizu T,Taniguchi K,Noda M,Neri P,Mori H

    更新日期:2008-04-16 00:00:00

  • Rubella seroprevalence in women in the reproductive period, Mersin, Turkey.

    abstract::The aim of this study was to determine the rubella seroprevalence in women of reproductive age. This cross-sectional study was conducted on women aged 15-49 years. Serologic studies were performed by using the ELISA method. The number of women enrolled in the study was 607, the mean age was 30.7+/-9.3 years and 13.2% ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.09.033

    authors: Sasmaz T,Kurt AO,Ozturk C,Bugdayci R,Oner S

    更新日期:2007-01-15 00:00:00

  • Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice.

    abstract::Rotavirus (RV) is the primary etiologic agent of severe gastroenteritis in human infants. Although two attenuated RV-based vaccines have been licensed to be applied worldwide, they are not so effective in low-income countries, and the induced protection mechanisms have not been clearly established. Thus, it is importa...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.03.080

    authors: Badillo-Godinez O,Gutierrez-Xicotencatl L,Plett-Torres T,Pedroza-Saavedra A,Gonzalez-Jaimes A,Chihu-Amparan L,Maldonado-Gama M,Espino-Solis G,Bonifaz LC,Esquivel-Guadarrama F

    更新日期:2015-08-20 00:00:00

  • Indicators to assess National Immunization Technical Advisory Groups (NITAGs).

    abstract::A National Immunization Technical Advisory Group (NITAG) is an expert advisory committee that provides evidence-based recommendations to the Ministry of Health (MoH) to guide immunization programs and policies. The World Health Organization (WHO), the Initiative for Supporting National Independent Immunization and Vac...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.01.047

    authors: Blau J,Sadr-Azodi N,Clementz M,Abeysinghe N,Cakmak N,Duclos P,Janusz C,Jauregui B,Mihigo R,Mosina L,Takashima Y,Senouci K

    更新日期:2013-05-28 00:00:00